RE:New Australian Study Discusses TLD1433 Loooong day at work...thanks Eoganacht for your continuing enlightenment of our ACT's potential. Dr. Mc Farland's successful research into the medicinal benefits of organometallic chemistry has truly opened the floodgates for future research & clinical trials re: this miraculous compound/technology, & it's nice to know TLT will ultimately be the beneficiary of its success.
What I find very encouraging is not only the recent wealth of research now being done in this field (in large part due to Dr. Mc Farland), but also the high degree of versatility this compound possesses outside of its ACT potential (I.e. the myriad formulations, treatment types & medical applications)...this unique attribute sometimes gets understated. I am particularly looking forward to clinical studies of its potential use as a combo or adjuvant drug. This is another area of need that TLT can address.
There are many combo treatment studies using Ruthenium complexes in cancer treatment that show great potential in offering synergistic advantages as well as the potential for reducing drug dosage (of TLTD-1433 &/or its partner drug), treatment toxicity & drug resistance. This type of clinical use could conceivably generate more revs than if used as a stand-alone option...possibly more so in the short term. Its use in combination with more conventional therapies could have the benefit of easing its clinical acceptance/adoption....helping transition docs out of their comfort zone of long-standing/more accepted practices to newer & less familiar protocols.
The following is just another example (abstract only) showing the promise & versatility of organometallic medicine/Ru complexes in defeating cancer...published today (3/2/2022). The study highlights the immunotherapeutic potential of Ru complexes that demonstrate the ability to reduce the effects of Tumor Associated Macrophages (TAMS)...TAMS exert pro-tumor effects by suppressing the body's natural immune response to cancer.
GLTA..
Metalloimmunotherapy with rhodium and ruthenium complexes: Targeting tumor-associated macrophages
First published: 02 March 2022
Abstract
Tumor associated macrophages (TAMs) suppress the cancer immune response and are a key target for immunotherapy. The effects of ruthenium and rhodium complexes on TAMs have not been well characterized. To address this gap in the field, a panel of 22 dirhodium and ruthenium complexes were screened against three subtypes of macrophages, triple-negative breast cancer and normal breast tissue cells. Experiments were carried out in 2D and biomimetic 3D co-culture experiments with and without irradiation with blue light. Leads were identified with cell-type-specific toxicity toward macrophage subtypes, cancer cells, or both. Experiments with 3D spheroids revealed complexes that sensitized the tumor models to the chemotherapeutic doxorubicin. Cell surface exposure of calreticulin, a known facilitator of immunogenic cell death (ICD), was increased upon treatment, along with a concomitant reduction in the M2-subtype classifier arginase. Our findings lay a strong foundation for the future development of ruthenium- and rhodium-based chemotherapies targeting TAMs.